Design And Development Of Sustained Release SLNS For Co-Delivery Of Ofloxacin And Meropenem

The current research is aimed at the design and development of Sustained Release Solid lipid nanoparticles (SLNs) to co-deliver 2 broad-spectrum antibiotics ofloxacin and Meropenem, that are commonly used in the case of severe bacterial infections. The conventional formulations of these antibiotics are hampered by the fact that they have a quick rate of systemic clearance, poor bioavailability, and the emerging problem of multidrug resistance. In order to overcome these problems, it was suggested to produce SLNs with the help of hot homogenization and ultrasonication with the addition of biocompatible lipids and surfactants. Characterization of physicochemical characteristics which involve particle size, zeta potential, polydispersity index (PDI), entrapment efficiency (EE%), and drug loading (DL%) was determined. Both drugs showed high EE% and nanoparticles of the SLNs had a uniform distribution with zeta potential favorable to allowing diffusion properties. In vitro study of drug release has shown sustained and controlled release within 24 hours. The capability of drugs to bind with lipids was ascertained by Fourier Transform Infrared Spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC) and the lack of chemical degradation. The antibacterial activity was determined using E. coli, S. aureus, K. pneumoniae and P. aeruginosa and in that case, the SLNs displayed remarkably improved zones of inhibition unlike free drugs. A statistical study by ANOVA, PCA confirmed the correlation of the formulation parameters with bioactivity. All in all, the co-delivery system developed on the basis of SLNs proved capable of enhancing the pharmacodynamic and pharmacokinetic profile of both drugs thus offering promise of increased therapeutic effectiveness and diminished resistivity. The paper provides an auspicious nanocarrier approach to deliver dual antibiotics effectively and over a wash time period during the administration of resistant bacterial infections.